急性骨髄性白血病治療薬の市場：疾患タイプ、治療タイプ、流通チャネル別-2025-2030年の世界予測

急性骨髄性白血病治療薬市場は、2023年に9億2,182万米ドルと評価され、2024年には10億2,156万米ドルに達すると予測され、CAGR 11.94％で成長し、2030年には20億3,049万米ドルに達すると予測されています。

急性骨髄性白血病（AML）治療薬の範囲は、異常な白血球の急速な増殖を特徴とする血液と骨髄を侵すがんの一種であるAMLの診断、治療、継続的な管理を含みます。効果的なAML治療薬が必要とされる背景には、高齢化に伴う発症率の増加があり、標的療法、化学療法、骨髄移植などの高度な治療法が必要とされています。これらの治療薬の用途には、寛解導入・強化、維持療法、再発・難治性AMLへの対応が含まれます。最終用途の範囲は、専門的な専門知識が集中する病院、がん専門クリニック、研究機関にほぼ限定されています。

AML治療薬の市場開拓は、個別化医療と標的治療の開発を可能にするゲノミクスの技術進歩が主な要因です。製薬会社、学術機関、研究機関の提携や協力関係が、技術革新とアクセシビリティをさらに後押ししています。しかし、高額な治療費、副作用、開発された医薬品の限定的な商業化といった制約が、臨床試験や規制当局の承認プロセスの複雑さと同様に、普及の妨げとなっています。新たなビジネスチャンスは、ドラッグデリバリーシステムの強化、患者層別化法の改善、毒性を抑えつつ治療効果を高めるための新規遺伝子マーカーの探索にあります。こうした機会を捉えるための推奨事項としては、研究開発への投資、戦略的提携によるリソースと専門知識の共有、個々の患者プロファイルに対応する精密医療アプローチへの注力などが挙げられます。

さらに、厳しい規制のために新薬の承認率が遅く、成功が保証されないまま多額の研究開発費がかかるといった課題にも直面しています。技術革新が必要な分野としては、コスト削減のためのバイオシミラーの開発、身体の免疫反応を利用する新規免疫療法、治療レジメンを動的に調整するためのリアルタイム患者モニタリング用デジタルツールなどが挙げられます。AML治療薬市場は、急速な技術革新、高い資本要件と規制上のハードルによる大きな参入障壁を特徴とするが、戦略的イノベーションとパートナーシップを通じてこれらの困難を乗り越えることに長けた企業にとっては計り知れない可能性を秘めています。

市場力学：急速に進化する急性骨髄性白血病治療薬市場の主要市場インサイトを公開

急性骨髄性白血病治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の急性骨髄性白血病患者の有病率
  • がん治療に対するニーズの高まりに伴うがん啓発プログラムの増加
  • 急性骨髄性白血病治療を支援する政府の好意的な取り組み
• 市場抑制要因
  • 急性骨髄性白血病治療薬の高コスト
• 市場機会
  • 新規急性骨髄性白血病治療薬の開発
  • 急性骨髄性白血病治療薬の承認率の上昇
• 市場の課題
  • 骨髄性白血病治療に伴う副作用

ポーターのファイブフォース：急性骨髄性白血病治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：急性骨髄性白血病治療薬市場における外部からの影響の把握

外部マクロ環境要因は、急性骨髄性白血病治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析急性骨髄性白血病治療薬市場における競合情勢の把握

急性骨髄性白血病治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス急性骨髄性白血病治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、急性骨髄性白血病治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨急性骨髄性白血病治療薬市場における成功への道筋を描く

急性骨髄性白血病治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 急性骨髄性白血病の世界の罹患率
    • がん治療の必要性が高まる中、がん啓発プログラムが増加
    • 急性骨髄性白血病治療を支援する政府の好ましい取り組み
  • 抑制要因
    • 急性骨髄性白血病治療の高額な費用
  • 機会
    • 急性骨髄性白血病の新たな治療法の開発
    • 急性骨髄性白血病治療薬の承認率上昇
  • 課題
    • 骨髄性白血病治療に伴う副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 急性骨髄性白血病治療薬の市場：疾患タイプ別

• 骨髄芽球性
• 骨髄単球性
• 前骨髄球性

第7章 急性骨髄性白血病治療薬の市場治療の種類別

• 化学療法
• 標的療法

第8章 急性骨髄性白血病治療薬の市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの急性骨髄性白血病治療薬の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の急性骨髄性白血病治療薬の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの急性骨髄性白血病治療薬の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Actinium Pharmaceuticals, Inc.
• Agios Pharmaceuticals, Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• Astex Pharmaceuticals, Inc. by Otsuka Group
• Celgene Corporation
• CTI BioPharma Corp.
• Cyclacel Pharmaceuticals, Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Janssen Global Services, LLC
• Jazz Pharmaceuticals PLC
• Johnson & Johnson Services, Inc.
• MEI Pharma, Inc.
• Merck & Co., Inc.
• Merus N.V.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• The Bristol Myers Squibb Company

LIST OF FIGURES

• FIGURE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MYELOBLASTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MYELOMONOCYTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PROMYELOCYTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Acute Myeloid Leukemia Therapeutics Market was valued at USD 921.82 million in 2023, expected to reach USD 1,021.56 million in 2024, and is projected to grow at a CAGR of 11.94%, to USD 2,030.49 million by 2030.

The scope of acute myeloid leukemia (AML) therapeutics involves the diagnosis, treatment, and ongoing management of AML, a form of cancer affecting the blood and bone marrow characterized by rapid growth of abnormal white blood cells. The necessity for effective AML therapeutics is driven by the increasing incidence of the disease, often related to aging populations, necessitating advanced treatment modalities like targeted therapies, chemotherapy, and bone marrow transplants. Applications of these therapeutics include induction and consolidation of remission, maintenance therapy, and addressing relapsed or refractory AML. End-use scope is largely restricted to hospitals, specialty cancer clinics, and research institutions, where specialized expertise is concentrated.

Market growth in AML therapeutics is primarily influenced by technological advancements in genomics, enabling personalized medicine and the development of targeted therapies. Partnerships and collaborations among pharmaceutical companies, academic institutions, and research bodies further fuel innovation and accessibility. However, constraints such as the high costs of treatment, side effects, and limited commercialization of developed drugs hinder widespread adoption, as does the complexity of clinical trials and regulatory approval processes. Emerging opportunities lie in enhancing drug delivery systems, improving patient stratification methods, and exploring novel genetic markers to increase therapeutic efficacy while reducing toxicity. Recommendations for capturing these opportunities include investing in R&D, forming strategic alliances to pool resources and expertise, and focusing on precision medicine approaches to cater to individual patient profiles.

Additionally, the market faces challenges like slow approval rates for new drugs because of stringent regulations, and significant R&D costs without guaranteed success. Areas ripe for innovation include the development of biosimilars to reduce costs, novel immunotherapies that harness the body's immune response, and digital tools for real-time patient monitoring to tailor treatment regimens dynamically. The AML therapeutics market is characterized by rapid technological change, substantial entry barriers due to high capital requirements and regulatory hurdles, but immense potential for companies adept at navigating these difficulties through strategic innovation and partnerships.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Myeloid Leukemia Therapeutics Market

The Acute Myeloid Leukemia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of acute myeloid leukemia cases worldwide
  • Increasing cancer awareness programs with growing need for cancer therapy
  • Favorable government initiatives to support the acute myeloid leukemia therapies
• Market Restraints
  • High cost of acute myeloid leukemia therapies
• Market Opportunities
  • Development of novel acute myeloid leukemia treatments
  • Rise in approval rate of acute myeloid leukemia therapeutics
• Market Challenges
  • Adverse effects associated with the myeloid leukemia treatment

Porter's Five Forces: A Strategic Tool for Navigating the Acute Myeloid Leukemia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Myeloid Leukemia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Myeloid Leukemia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Myeloid Leukemia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Myeloid Leukemia Therapeutics Market

A detailed market share analysis in the Acute Myeloid Leukemia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Myeloid Leukemia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Myeloid Leukemia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Myeloid Leukemia Therapeutics Market

A strategic analysis of the Acute Myeloid Leukemia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Myeloid Leukemia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Actinium Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc. by Otsuka Group, Celgene Corporation, CTI BioPharma Corp., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Janssen Global Services, LLC, Jazz Pharmaceuticals PLC, Johnson & Johnson Services, Inc., MEI Pharma, Inc., Merck & Co., Inc., Merus N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and The Bristol Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Acute Myeloid Leukemia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Myeloblastic, Myelomonocytic, and Promyelocytic.
• Based on Treatment Type, market is studied across Chemotherapy and Targeted Therapy.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of acute myeloid leukemia cases worldwide
    • 5.1.1.2. Increasing cancer awareness programs with growing need for cancer therapy
    • 5.1.1.3. Favorable government initiatives to support the acute myeloid leukemia therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of acute myeloid leukemia therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel acute myeloid leukemia treatments
    • 5.1.3.2. Rise in approval rate of acute myeloid leukemia therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with the myeloid leukemia treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Myeloid Leukemia Therapeutics Market, by Disease Type

• 6.1. Introduction
• 6.2. Myeloblastic
• 6.3. Myelomonocytic
• 6.4. Promyelocytic

7. Acute Myeloid Leukemia Therapeutics Market, by Treatment Type

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Targeted Therapy

8. Acute Myeloid Leukemia Therapeutics Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Americas Acute Myeloid Leukemia Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Acute Myeloid Leukemia Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Acute Myeloid Leukemia Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Actinium Pharmaceuticals, Inc.
• 3. Agios Pharmaceuticals, Inc.
• 4. Amgen Inc.
• 5. Astellas Pharma Inc.
• 6. Astex Pharmaceuticals, Inc. by Otsuka Group
• 7. Celgene Corporation
• 8. CTI BioPharma Corp.
• 9. Cyclacel Pharmaceuticals, Inc.
• 10. Daiichi Sankyo Company, Limited
• 11. Eisai Co., Ltd.
• 12. F. Hoffmann-La Roche AG
• 13. GlaxoSmithKline plc
• 14. Janssen Global Services, LLC
• 15. Jazz Pharmaceuticals PLC
• 16. Johnson & Johnson Services, Inc.
• 17. MEI Pharma, Inc.
• 18. Merck & Co., Inc.
• 19. Merus N.V.
• 20. Novartis AG
• 21. Pfizer Inc.
• 22. Sanofi S.A.
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Takeda Pharmaceutical Company Limited
• 25. Teva Pharmaceutical Industries Ltd.
• 26. The Bristol Myers Squibb Company